The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Berkkan M, Kıkılı Cİ, Köylü B, Kemik F, Demir N, Sönmez E, Kula S, Tural D, Selçukbiricik F

Alpelisib-induced severe interstitial lung disease: case report.

Journal of chemotherapy (Florence, Italy) 2026 Jan 02; — 2026 Jan 02 — 1-8

Isiklar A, Basaran G, Sepin B, Gumusay O, Kocagoz AS, Cuhadaroglu C

Alpelisib induced interstitial lung disease in a patient with advanced breast cancer.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2022 Jun 22;;10781552221107532 — 2022 Jun 22 — 10781552221107532